ArticlePharmaceutics2024

Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer.

Paul M Kuhn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.